These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8829882)

  • 41. Recovery of epidermal growth factor in voided urine of patients with bladder cancer.
    Messing EM; Murphy-Brooks N
    Urology; 1994 Oct; 44(4):502-6. PubMed ID: 7941190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker.
    Chen YT; Hayden CL; Marchand KJ; Makuch RW
    J Urol; 1997 Nov; 158(5):1899-901. PubMed ID: 9334626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.
    Eissa S; Matboli M; Essawy NO; Shehta M; Kotb YM
    Biomarkers; 2015; 20(3):212-7. PubMed ID: 26161701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
    Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
    Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder.
    Appunni S; Anand V; Khandelwal M; Seth A; Mathur S; Sharma A
    Tumour Biol; 2017 May; 39(5):1010428317699112. PubMed ID: 28459201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.
    Shimwell NJ; Bryan RT; Wei W; James ND; Cheng KK; Zeegers MP; Johnson PJ; Martin A; Ward DG
    Br J Cancer; 2013 May; 108(9):1854-61. PubMed ID: 23591195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of a bladder tumor antigen test for the diagnosis of lower urinary tract malignancies in dogs.
    Billet JP; Moore AH; Holt PE
    Am J Vet Res; 2002 Mar; 63(3):370-3. PubMed ID: 11926180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical studies on the measurement of urinary tissue polypeptide antigen (TPA) levels using Prolifigen TPA kit "Daiichi"-II in urothelial cancers].
    Ohmori H; Ohashi T; Aso Y; Kumamoto Y; Hisazumi H; Shiraiwa Y; Kurita T; Shimazaki J; Ohkawa T; Ogawa H
    Hinyokika Kiyo; 1988 Dec; 34(12):2101-10. PubMed ID: 3071123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. H19 non-coding RNA in urine cells detects urothelial carcinoma: a pilot study.
    Gielchinsky I; Gilon M; Abu-Lail R; Matouk I; Hochberg A; Gofrit ON; Ben-Dov IZ
    Biomarkers; 2017 Nov; 22(7):661-666. PubMed ID: 28067543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune signature of urothelial cancer associated with grade, recurrence, and invasion.
    Agrawal U; Kumari N; Mishra AK; Vasudeva P; Kumar A; Mohanty NK; Saxena S
    Urol Oncol; 2016 Sep; 34(9):418.e17-26. PubMed ID: 27554791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment.
    Weingärtner K; Ben-Sasson SA; Stewart R; Richie JP; Riedmiller H; Folkman J
    J Urol; 1998 Feb; 159(2):465-70. PubMed ID: 9649264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.
    Li VW; Folkerth RD; Watanabe H; Yu C; Rupnick M; Barnes P; Scott RM; Black PM; Sallan SE; Folkman J
    Lancet; 1994 Jul; 344(8915):82-6. PubMed ID: 7516992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of the role of serum vascular endothelial growth factor and urinary basic fibroblast growth factor in differential diagnosis of vascular anomalies].
    Zhang L; Chen Q; Li D; Li XW; Wang HG; Li GZ
    Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1092-5. PubMed ID: 21609589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of diffusion-weighted MRI post-CT urography for the diagnosis of upper tract urothelial carcinoma: Comparison with selective urine cytology sampling.
    Akita H; Kikuchi E; Hayakawa N; Mikami S; Sugiura H; Oya M; Jinzaki M
    Clin Imaging; 2018; 52():208-215. PubMed ID: 30125847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
    Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
    Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The occult urothelial cancer.
    Ragonese M; Racioppi M; D'Agostino D; Di Gianfrancesco L; Lenci N; Bientinesi R; Palermo G; Sacco E; Pinto F; Bassi PF
    Urologia; 2016 May; 83(2):55-60. PubMed ID: 26481721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.